drugset / Trial / NCT00982033
Effects of Aliskiren on Patient With Heart Failure and a Normal Ejection Fraction
Phase 4
Completed
52 enrolled
Wake Forest University Health Sciences
Novartis Pharmaceuticals · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The primary objective of this study is to determine whether treatment with aliskiren (300 mg) compared to placebo will improve treadmill exercise time in older (age ≥ 55 years) patients with heart failure and normal ejection fraction (HFNEF).
Timeline
- Start
- 2009-07
- Primary completion
- 2011-09
- Completion
- 2011-12
Publications
- Results Scott JM, Haykowsky MJ, Eggebeen J, Morgan TM, Brubaker PH, Kitzman DW. Reliability of peak exercise testing in patients with heart failure with preserved ejection fraction. Am J Cardiol. 2012 Dec 15;110(12):1809-13. doi: 10.1016/j.amjcard.2012.08.015. Epub 2012 Sep 13.
- Upadhya B, Brubaker PH, Morgan TM, Eggebeen JD, Jao GT, Stewart KP, Kitzman DW. The effect of Aliskiren on exercise capacity in older patients with heart failure and preserved ejection fraction: A randomized, placebo-controlled, double-blind trial. Am Heart J. 2018 Jul;201:164-167. doi: 10.1016/j.ahj.2018.03.019. Epub 2018 Apr 4.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Aliskiren | Small molecule | 300 mg | — |